June 30, 2021
1 min read

 Covaxin effective against both Alpha, Delta variants: US NIH

COVAXIN comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus…reports Asian Lite News

The National Institute of Health (NIH) in the United States has found that Bharat Biotech’s COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19.

The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the “highly efficacious” COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.

“Results from two studies of blood serum from people who had received COVAXIN suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively,” NIH said in a statement.

The adjuvant used in COVAXIN, Alhydroxiquim-II, was discovered and tested in the laboratory by the biotech company ViroVax LLC of Lawrence, Kansas with support exclusively from the NIAID Adjuvant Development Program, NIH said.

ALSO READ: ‘FDA decision on Covaxin has no bearing on us’

The adjuvant comprises a small molecule attached in a unique way to Alhydrogel, a substance frequently called alum that is the most commonly used adjuvant in vaccines for people.

“Ending a global pandemic requires a global response,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. “I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious COVID-19 vaccine available to people in India.”

COVAXIN comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus. Published results from a Phase 2 trial of the vaccine indicate that it is safe and well-tolerated.

Unpublished interim results from the Phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against severe COVID-19, including hospitalization, and 70 per cent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19. (ANI)

ALSO READ: Covaxin trials on children set to begin

Previous Story

Burmese grapes from Assam exported to Dubai

Next Story

Modi holds high-level meet on security issues

Latest from -Top News

Nepal rescues over 1,500 stranded tourists

Nepali Army leads massive rescue of 1,500 trekkers stranded in Manang after heavy snowfall….reports Asian Lite News Nepali security forces have successfully rescued more than 1,500 trekkers, including over 200 foreign tourists,

Trump and Xi try reset in Busan

Trump and Xi strike conciliatory tone in Busan, hinting at a trade deal amid tariff disputes, fentanyl talks, and Trump’s shock nuclear weapons testing order….reports Asian Lite News In their first face-to-face

A new India-UAE cultural bridge

UAE and India reaffirm creative collaboration at New Delhi cultural roundtable, spotlighting the India House initiative and deepening ties through shared heritage, innovation, and artistic exchange…reports Asian Lite News The Embassy of

India, China reaffirm border peace

India and China reaffirm border peace during 23rd round of Corps Commander talks, pledging to maintain dialogue and stability under leaders’ consensus for long-term calm….reports Asian Lite News India and China have

Modi dials Takaichi

Modi, Takaichi reaffirm shared commitment to strengthen India-Japan partnership amid global security shifts…reports Asian Lite News Prime Minister Narendra Modi spoke with Japan’s new Prime Minister, Sanae Takaichi, and congratulated her on
Go toTop

Don't Miss

Covaxin gets emergency use approval for kids aged 2-18 years

Public health experts says move can turn out to be

Covaxin 77.8% effective after Phase 3 trials

Bharat Biotech’s Covaxin is overall 77.8 percent effective against Covid,